Your browser doesn't support javascript.
loading
New insights into the clinical and molecular spectrum of the novel CYFIP2-related neurodevelopmental disorder and impairment of the WRC-mediated actin dynamics.
Begemann, Anaïs; Sticht, Heinrich; Begtrup, Amber; Vitobello, Antonio; Faivre, Laurence; Banka, Siddharth; Alhaddad, Bader; Asadollahi, Reza; Becker, Jessica; Bierhals, Tatjana; Brown, Kathleen E; Bruel, Ange-Line; Brunet, Theresa; Carneiro, Maryline; Cremer, Kirsten; Day, Robert; Denommé-Pichon, Anne-Sophie; Dyment, Dave A; Engels, Hartmut; Fisher, Rachel; Goh, Elaine S; Hajianpour, M J; Haertel, Lucia Ribeiro Machado; Hauer, Nadine; Hempel, Maja; Herget, Theresia; Johannsen, Jessika; Kraus, Cornelia; Le Guyader, Gwenaël; Lesca, Gaetan; Mau-Them, Frédéric Tran; McDermott, John Henry; McWalter, Kirsty; Meyer, Pierre; Õunap, Katrin; Popp, Bernt; Reimand, Tiia; Riedhammer, Korbinian M; Russo, Martina; Sadleir, Lynette G; Saenz, Margarita; Schiff, Manuel; Schuler, Elisabeth; Syrbe, Steffen; Van der Ven, Amelie Theresa; Verloes, Alain; Willems, Marjolaine; Zweier, Christiane; Steindl, Katharina; Zweier, Markus.
Afiliação
  • Begemann A; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
  • Sticht H; Institute of Biochemistry, Emil-Fischer Center, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Begtrup A; GeneDx, Gaithersburg, MD, USA.
  • Vitobello A; INSERM UMR 1231 Equipe GAD, Université de Bourgogne, Dijon, France.
  • Faivre L; Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
  • Banka S; INSERM UMR 1231 Equipe GAD, Université de Bourgogne, Dijon, France.
  • Alhaddad B; Centre de Référence Maladies Rares «Anomalies du développement et syndromes malformatifs¼, centre de génétique, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
  • Asadollahi R; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Becker J; Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Bierhals T; Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
  • Brown KE; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
  • Bruel AL; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.
  • Brunet T; Institute of Human Genetics, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
  • Carneiro M; University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, CO, USA.
  • Cremer K; INSERM UMR 1231 Equipe GAD, Université de Bourgogne, Dijon, France.
  • Day R; Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
  • Denommé-Pichon AS; Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
  • Dyment DA; Department of Neuropediatrics, Lyon University Hospital, Lyon, France.
  • Engels H; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.
  • Fisher R; Cancer Research Laboratory, Department of Biochemistry, University of Otago, Dunedin, New Zealand.
  • Goh ES; INSERM UMR 1231 Equipe GAD, Université de Bourgogne, Dijon, France.
  • Hajianpour MJ; Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
  • Haertel LRM; Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada.
  • Hauer N; Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada.
  • Hempel M; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.
  • Herget T; Division of Pediatric Genetics, Metabolism, and Genomic Medicine, Department of Pediatrics, University of Michigan, Arbor, MI, USA.
  • Johannsen J; Laboratory Medicine and Genetics and Institute for Better Health, Trillium Health Partners, Mississauga, ON, Canada.
  • Kraus C; Department of Pediatrics, Medical Genetics, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA.
  • Le Guyader G; Hospital Santa Catarina de Blumenau, Blumenau, Brazil.
  • Lesca G; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Mau-Them FT; Institute of Human Genetics, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
  • McDermott JH; Institute of Human Genetics, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
  • McWalter K; Department of Pediatrics, University medical center Hamburg-Eppendorf, Hamburg, Germany.
  • Meyer P; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Õunap K; CHU de Poitiers, Poitiers, France.
  • Popp B; Department of Medical Genetics, Lyon University Hospital, Lyon, France.
  • Reimand T; CNRS UMR 5292, INSERM U1028, Claude Bernard Lyon 1 University, Lyon, France.
  • Riedhammer KM; INSERM UMR 1231 Equipe GAD, Université de Bourgogne, Dijon, France.
  • Russo M; Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
  • Sadleir LG; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Saenz M; Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Schiff M; GeneDx, Gaithersburg, MD, USA.
  • Schuler E; Department of Pediatric Neurology, CHU Montpellier, PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.
  • Syrbe S; Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
  • Van der Ven AT; Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia.
  • Verloes A; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Willems M; Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany.
  • Zweier C; Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
  • Steindl K; Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia.
  • Zweier M; Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Genet Med ; 23(3): 543-554, 2021 03.
Article em En | MEDLINE | ID: mdl-33149277
ABSTRACT

PURPOSE:

A few de novo missense variants in the cytoplasmic FMRP-interacting protein 2 (CYFIP2) gene have recently been described as a novel cause of severe intellectual disability, seizures, and hypotonia in 18 individuals, with p.Arg87 substitutions in the majority.

METHODS:

We assembled data from 19 newly identified and all 18 previously published individuals with CYFIP2 variants. By structural modeling and investigation of WAVE-regulatory complex (WRC)-mediated actin polymerization in six patient fibroblast lines we assessed the impact of CYFIP2 variants on the WRC.

RESULTS:

Sixteen of 19 individuals harbor two previously described and 11 novel (likely) disease-associated missense variants. We report p.Asp724 as second mutational hotspot (4/19 cases). Genotype-phenotype correlation confirms a consistently severe phenotype in p.Arg87 patients but a more variable phenotype in p.Asp724 and other substitutions. Three individuals with milder phenotypes carry putative loss-of-function variants, which remain of unclear pathogenicity. Structural modeling predicted missense variants to disturb interactions within the WRC or impair CYFIP2 stability. Consistent with its role in WRC-mediated actin polymerization we substantiate aberrant regulation of the actin cytoskeleton in patient fibroblasts.

CONCLUSION:

Our study expands the clinical and molecular spectrum of CYFIP2-related neurodevelopmental disorder and provides evidence for aberrant WRC-mediated actin dynamics as contributing cellular pathomechanism.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos do Neurodesenvolvimento / Deficiência Intelectual Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos do Neurodesenvolvimento / Deficiência Intelectual Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article